We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Immunoassays for Enzyme and Inhibitors Predict Breast Cancer

By LabMedica International staff writers
Posted on 01 Mar 2011
Print article
Immunoenzymatic assays have been used to detect serum concentrations of matrix metalloproteinases (MMPs) and their tissue inhibitors in patients with breast cancer.

Serum levels of MMP-2, family of zinc-dependent endopeptidases and the endogenous inhibitors of MMPs, the tissue inhibitors of metalloproteinases (TIMPs) can be measured either by profiling kits and enzyme linked immunosorbent assays (ELISA).

A study carried out at the University of Athens, (Athens, Greece), examined the serum concentration of the enzymes and inhibitors from a cohort of women with nonpalpable breast lesions who were followed for 24 months. Serum MMP-2 concentrations were measured using Fluorokine MultiAnalyte Profiling kits in a Luminex Bioanalyzer (Luminex Corp, TX, USA). Levels of the inhibitors TIMP-1 and TIMP-2 and other tumor markers were assessed using ELISA methods.

The scientists assessed serum concentrations of MMP1, MMP-2, TIMP-1, and TIMP-2 in atypical ductal hyperplasia (ADH), lobular neoplasia (LN), ductal carcinoma in situ (DCIS) and invasive ductal carcinoma (IDC) specifically in nonpalpable breast lesions found after mammography. The serum TIMPs and other tumor markers were assessed by ELISA methods from R&D Systems, (Minneapolis, MN, USA), and IDL Biotech AB, (Bromma, Sweden).

Serum TIMP-2 concentrations were positively associated with the severity of the lesion. Conversely, MMP-2 levels were marginally negatively associated with severity; as evident, the MMP-2/TIMP-2 ratio significantly decreased along with severity. No significant associations were demonstrated between the other biomarkers tested and breast cancer carcinogenesis. The MMP-2 serum levels and the MMP-2/TIMP-2 ratio were significantly higher in the LN subgroup compared with the ADH subgroup.

The authors concluded that TIMP-2 was associated with more severe diagnosis in nonpalpable lesions and that the MMP-2/TIMP-2 ratio may exhibit meaningful changes along with progression of lesions. Extracellular cell matrix remodeling in ductal and lobular lesions appears to follow distinct patterns. The study has been available online since December 3, 2010, in the journal Clinica Chimica Acta.

Related Links:

University of Athens
Luminex Corp.
R&D Systems
IDL Biotech AB


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Vaginitis Test
Allplex Vaginitis Screening Assay

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.